STALICLA is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders.
Stalicla has raised $13.6M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Stalicla's investors include LIFTT, SPRIM Global Investments, AA Sons.
Stalicla is headquartered in Genîve, Switzerland.
STALICLA is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders.
Stalicla is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Stalicla — Funding & Investors." VCBacked, January 16, 2024, https://www.vcbacked.co/company/stalicla. Accessed July 28, 2026.
VCBacked. (2024). Stalicla — Funding & Investors. Retrieved July 28, 2026, from https://www.vcbacked.co/company/stalicla
{{cite web |title=Stalicla — Funding & Investors |url=https://www.vcbacked.co/company/stalicla |website=VCBacked |access-date=July 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated